Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-24-000073
Filing Date
2024-11-07
Accepted
2024-11-07 16:13:00
Documents
71
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20240930.htm   iXBRL 10-Q 1653887
2 EX-31.1 allo-20240930xex311.htm EX-31.1 9786
3 EX-31.2 allo-20240930xex312.htm EX-31.2 9736
4 EX-32.1 allo-20240930xex321.htm EX-32.1 7002
  Complete submission text file 0001737287-24-000073.txt   7982782

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20240930.xsd EX-101.SCH 63597
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20240930_cal.xml EX-101.CAL 55651
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20240930_def.xml EX-101.DEF 416151
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20240930_lab.xml EX-101.LAB 758619
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20240930_pre.xml EX-101.PRE 570392
74 EXTRACTED XBRL INSTANCE DOCUMENT allo-20240930_htm.xml XML 857660
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 241435844
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)